Author

Vincent Roy

Université d'OrléansORCID 0000-0002-2491-6019Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Vincent Roy1 paper · Université de Sherbrooke

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Organism:human· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

Franck GallardoiD· 3 shared Luigi André AgrofoglioiD· 3 shared Sandrine Kappler‐Gratias· 3 shared Charlotte Quentin-FroignantiD· 2 shared Elie MarcheteauiD· 2 shared Károly TóthiD· 2 shared Alicia MasiD· 1 shared Alı́ AlejoiD· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Franck GallardoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

LAVR-289, a new acyclo-nucleoside phosphonate having broad-spectrum activity against herpesviruses.

Sandrine Kappler‐Gratias, Charlotte Quentin-Froignant, Elie Marcheteau, José Fernandez, David Boutolleau, Virginie Garcia, Vincent Roy, Luigi André Agrofoglio, Franck Gallardo

This study evaluates LAVR-289, a new antiviral compound, showing broad-spectrum activity against herpesviruses and resistance to existing treatments.

bioRxiv · Feb 20, 2025 · PreprintMicrobiology

LAVR-289, a New Orally Bioavailable Inhibitor of Adenovirus Replication in vitro and in vivo.

Charlotte Quentin-Froignant, Ann E. Tollefson, Anna Cline-Smith, Sandrine Kappler‐Gratias, Nicolas Landrein, Vincent Roy, Luigi André Agrofoglio, Károly Tóth, Harald Wodrich, Franck Gallardo

This study evaluates LAVR-289, an acyclonucleoside phosphonate, showing potent antiviral activity against adenovirus in vitro and in vivo, with 100% survival in immunocompromised hamsters.

bioRxiv · Feb 20, 2025 · PreprintMicrobiology

In vitro and in vivo Antiviral Activity of the Acyclic Nucleoside Phosphonate Prodrug LAVR-289 against Poxvirus and African Swine Fever Virus Replication

Elie Marcheteau, Estelle Mosca, Gaelle Frénois-Veyrat, Sandrine Kappler‐Gratias, Laetitia Boutin, Sokunthea Top, Thomas Mathieu, Cyril Colas, Patrick Favetta, Tony Garnier, Peggy Barbe, Mathilde Keck, Daniel Gillet, Alicia Mas, Alı́ Alejo, , Franck Gallardo

This study evaluates LAVR-289, a nucleoside analogue, showing antiviral activity against poxviruses and ASFV in vitro and in vivo with no toxicity.

bioRxiv · Feb 20, 2025 · PreprintMicrobiology